A phase III trial of efficacy of the FML-vaccine against canine kala-azar in an endemic area of Brazil (São Gonçalo do Amaranto, RN).

Abstract

Protection against canine kala-azar was investigated in naturally exposed dogs of an endemic area, vaccinated with the fucose mannose ligand (FML)-vaccine of Leishmania donovani. A total of 97% of vaccinees were seropositive to FML and 100% showed intradermal reaction to L. donovani lysate, 7 months after vaccination. The absorbency values and size of intradermal reaction were both significantly higher in vaccinees than in controls (ANOVA, P<0.0001). After 2 years, 92% (chi(2)=6.996; P<0.0025) protection was achieved: only 8% of vaccinees showed mild signs of kala-azar with no deaths while 33% of controls developed clinical or fatal disease. The FML-vaccine induced a significant, long-lasting and strong protective effect against canine kala-azar in the field.

• Authors: V O da Silva, G P Borja-Cabrera, N N Correia Pontes, E P de Souza, K G Luz, M Palatnik, C B Palatnik de Sousa
• Journal: Vaccine (Vaccine) Vol. 19 Issue 9-10 Pg. 1082-92 (Dec 08 2000) ISSN: 0264-410X [Print] Netherlands
• PMID: 11137242 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Lectins
• Protozoan Vaccines
• fucose-binding lectin

Topics

• Animals
• Brazil
• Dogs
• Lectins (immunology)
• Leishmania donovani (immunology)
• Leishmaniasis, Visceral (prevention & control)
• Protozoan Vaccines (immunology)
• Vaccination
• Zoonoses